Zhengye Biotechnology Holding Ltd. ZYBT

What this company does

The company, through the operating entity, focuses on the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. The operating entity's products are sold in 29 provincial regions across China and are exported to Vietnam, Pakistan and Egypt. The operating entity's product portfolio includes 50 veterinary vaccines, covering monovalent, polyvalent, combined, and combined and polyvalent vaccines for livestock. The operating entity has built three veterinary vaccine production floors, including 13 vaccine production lines, one quality examination center, and one animal facility for vaccine development. As of December 31, 2025, the operating entity had 269 full-time employees. For the fiscal year ended December 31, 2025, the operating entity had a total of 223 customers, of which 98 were direct end-user customers and 121 were distributor customers. Jilin Zhengye, the operating entity, was established as a limited liability company organized under the laws of the PRC on May 18, 2004.

Written from the business description in Zhengye Biotechnology Holding Limited's annual report to the U.S. Securities and Exchange Commission, filed 28 April 2026. Every sentence was checked against that document before publication.